The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
The following day, Foreign Minister Sihasak Phuangketkeow was named as Bhumjaithai's second candidate for prime minister as a backup. On 25 December, Pheu Thai announced its list of 500 candidates to contest every House seat. Anutin ruled out any coalition between Bhumjaithai and parties seeking to amend Article 112 on lèse-majesté following statements by Natthaphong that the People's Party would never vote for Anutin to become prime minister again. On 26 December, the Democrat Party announced its three candidates for prime minister: party leader Abhisit Vejjajiva, Korn Chatikavanij, and Karndee Leopairote, at its headquarters in Bangkok. Palang Pracharath Party leader Prawit Wongsuwon announced his intention to retire from politics after withdrawing as one of the party's three prime ministerial candidates. His withdrawal as a prime ministerial candidate was joined by deputy party leader Thirachai Phuvanatnaranubala, who also announced his withdrawal from politics. On 28 December, representatives from 52 political parties registered their parties' lists of prime ministerial and party-list candidates.
Altria, like other tobacco companies, has invested in science and medical companies which develop and produce medical products for conditions caused or aggravated by smoking. As of 2024, Altria's three medical subsidiaries included the following: Cronos group (maker of recreational cannabis), Lexaria Bioscience (Developer of proprietary drug delivery technology, DehydraTECH, to improve active pharmaceutical ingredients entrance into the bloodstream) and Micreos (biotech company focused on discovering and developing recombinant proteins for chronic dermatology and oncology conditions). It has also designed and marketed electronic cigarettes. Altria launched the MarkTen and Green Smoke brands. Both of these were discontinued in December 2018. The company returned to this market through the acquisition of NJOY.
The mass number of this isotope was not clearly established (possibly 258 or 259) at the time. In 1965, 256Lr was synthesized by Flyorov et al. from 243Am and 18O. Thus IUPAC recognized the nuclear physics teams at Dubna and Berkeley as the co-discoverers of lawrencium.
Substituted phenethylamines (or simply phenethylamines) are a chemical class of organic compounds that are based upon the phenethylamine structure; the class is composed of all the derivative compounds of phenethylamine which can be formed by replacing, or substituting, one or more hydrogen atoms in the phenethylamine core structure with substituents. Phenylethylamines are also generally found to be central nervous system stimulants with many also being entactogens/empathogens, and hallucinogens.
Each house consisted of members elected to represent constituencies, plus a few additional members elected by the MPs, and some nominated by the State President. Each house legislated on "own affairs" exclusive to its own race group, and they legislated jointly on "general affairs" affecting all races. In practice, the House of Assembly, which had more MPs than the other two houses combined, continued to dominate the legislature. Each house was chaired by a chairman elected by its members from among themselves. They were coordinated by a Speaker of Parliament, elected by the members of all three houses in a joint sitting. The existing House of Assembly, elected in 1981, was deemed to have been re-elected in 1984, to coordinate its term of office with those of the two new houses. However, this was later overturned by the Supreme Court, and a separate election had to be held for the House of Assembly in 1987. The House elected in 1987 was then dissolved with the other houses in 1989. The black majority were still disfranchised, and the new system lacked legitimacy even among the Coloureds and Asians, many of whom boycotted elections. In a referendum held in 1992, 68.73% of (only white) voters approved the reform process that effectively ended Apartheid. In late 1993, one of the last pieces of legislation passed by the tricameral Parliament was the Interim Constitution, which took effect on 27 April 1994, the same day as the first non-racial elections.
Sources: en.wikipedia.org
As benzene can cause cancer, National Institute for Occupational Safety and Health recommends that all workers wear special breathing equipment when they are likely to be exposed to benzene at levels exceeding the recommended (8-hour) exposure limit of 0.1 ppm. According to Occupational Safety and Health Administration’s Supporting Statement for the Information Collection Request for the Benzene standard, an estimated 12,270 establishments are subject to the requirements of the standard.
== History == Nicotinamide riboside (NR) has been identified as an NAD precursor, involved in salvage NAD synthesis in both bacteria and eukaryotes. In bacteria, it was first described in 1944 as a necessary growth factor for the culture of Haemophilus influenzae, H. influenzae was identified as requiring both X factor (hemin) and V factor (NAD) to grow. V factor, purified from blood, was shown to exist in three forms: nicotinamide adenine dinucleotide (NAD), NMN and NR. NR was the compound that led to the most rapid growth of the H. influenzae bacterium. H. influenzae cannot grow on nicotinic acid (NA), nicotinamide (NAM), or amino acids such as tryptophan (Trp) or aspartic acid (Asp), which were the previously known precursors of NAD. H. influenzae depends entirely on salvage of NAD precursors from other cells in its environment. The identification of nicotinamide riboside (NR) as an NAD precursor in eukaryotes developed out of the study of pellagra. Pellagra was the first disease to be associated with NAD deficiency. It was linked to nutritional deficiency by Joseph Goldberger in 1914, and to deficiency of niacin (vitamin B3) by Conrad Elvehjem in 1937. NAD (then called coenzyme I) was shown to be extremely low in cases of pellagra, and NA and NAM were identified as molecular precursors in rebuilding NAD levels. Pellagra is now understood as a severe, chronic depletion of NAD, which can be treated through diet. Subsequent studies of NAD metabolism have identified regulatory pathways used by cells and tissues to maintain NAD availability.
=== MSNovelist: De novo structure prediction === MSNovelist is a computational method for the de novo generation of small molecule structures. It addresses a key limitation of database search tools, which can only identify compounds already present in reference structure databases. This makes it particularly useful for analyzing poorly represented analyte classes and novel compounds. It is not intended to replace database searches altogether, but generates structures which can serve as a great starting point for elucidation of specific unknowns. MSNovelist functions by generating novel molecular structures based on the molecular formula (identified by SIRIUS) and the molecular fingerprint (predicted by CSI:FingerID) of the unknown compound. An encoder–decoder recurrent neural network (RNN) model is trained to translate the input fingerprint into a structure, represented as a SMILES sequence, under the constraints of the predicted molecular formula. MSNovelist generates multiple candidate structures from the predicted molecular fingerprint. Once the candidate structures are generated, they are ranked using CSI:FingerID.
=== Canada === Federally, carisoprodol is a prescription drug. Provincial regulations vary. As of April 2025, no forms of carisoprodol are marketed in Canada, and the drug was removed from the Prescription Drug List and reclassified as a Schedule V Controlled Substance.
=== Sweat gland nerve fiber density === Sweat gland nerve fiber density (SGNFD) can be quantified in skin biopsies taken from the distal leg, distal thigh, and proximal thigh prepared for standard analysis of intraepidermal nerve fiber density (IENFD). Nerve fibers innervating sweat glands are stained with Protein Gene Product 9.5 and quantified using manual morphometry with light microscopy. SGNFD can potentially be used as a surrogate anatomical marker for sudomotor function. However, it is not a direct assessment of the sweat response, and normative data must be established.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.